Mechanism of Action
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose, and…
Clinical Trials (5)
OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
Loss of Exclusivity
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 6515117 | Oct 4, 2025Expired | SubstanceProduct | U-493 |
| 6515117*PED | Apr 4, 2026 | — | |
| 8501698 | Jun 20, 2027 | Product | U-493 |
| 8501698*PED | Dec 20, 2027 | — | |
| 7919598 | Dec 16, 2029 | Substance | — |